Navigation Links
How chemo kills tumors: research to reduce side effects
Date:8/6/2008

er Cell (August 2008), have shown how different tumours respond to the anti-mitotic drugs which target the mitotic spindle (the structure that separates the chromosomes during cell division) and revealed that the variation in cell behaviour was far greater than previously recognized.

They used a high throughput automated time-lapse light microscopy approach to systematically analyze over 10,000 single cells from 15 cell lines in response to three different classes of anti-mitotic drug. This revealed the large variation in cell behavior with cells within any given line exhibiting multiple fates.

Dr Taylor explained: "We know that anti-mitotic drugs block the final stage of the cell division process, mitosis. How the cells then die is a mystery.

"We embarked on a fresh, more direct approach that is actually quite simple. Basically, we just watched the cells using time-lapse microscopy; this allowed us to track the behaviour of individual cells and determine their fate when exposed to different anti-mitotic drugs.

"The first thing we realised was that the picture was much more complicated that we originally thought; the range of different behaviours was profound. Not only did cells from different cell lines behave differently, but cells within the same line also behaved differently.

"The level of complexity was at first overwhelming. However, as we slowly made our way through the data, patterns began to emerge. This allowed us to formulate a new hypothesis. We were then able to design more experiments to test this hypothesis.

"In essence, it turns out that when cells are exposed to these drugs they arrest in mitosis. Then a race starts between two competing cellular signalling networks. One network is trying to kill the cell, the other is trying to cause the cell to exit mitosis and thus allow the cell to survive. The winner of the race decides the fate of the cell; death or survival.

"The factors inf
'/>"/>

Contact: Mikaela Sitford
Mikaela.Sitford@manchester.ac.uk
01-612-752-111
University of Manchester
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
2. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
3. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
6. A search for protection against chemotherapy cardiotoxicity
7. UC health news: molecular pathway may predict chemotherapy effectiveness
8. Food scientists confirm commercial product effectively kills bacteria in vegetable washwater
9. New UGA invention effectively kills foodborne pathogens in minutes
10. Mounting evidence shows red wine antioxidant kills cancer
11. New decontamination system kills anthrax rapidly without lingering effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ... period 2013 through 2020. Also, a seven-year historic analysis is provided ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... old, have been ill, or suffered an injury, you,ve watched ... slight or gradualis about as common to the human condition ... little about what causes skeletal muscles to atrophy. They know ... and parsing the key actors from the poseurs is tricky. ...
... A broken chromosome is like an unmoored beansprout circling in ... with broken chromosomes, the cell will be killed and so ... Often, it finds a workable substitute: another nearby chromosome. When ... a similar process to exchange genetic material, you,ve got a ...
... found a way to replace up to 50 per cent ... Warwick chemists have taken out much of the cocoa butter ... with tiny droplets of juice measuring under 30 microns in ... dark and white chocolate using what is known as a ...
Cached Biology News:Researchers identify key culprit causing muscle atrophy 2Researchers identify key culprit causing muscle atrophy 3Chromosomal translocations point the way toward personalized cancer care 2Chromosomal translocations point the way toward personalized cancer care 3Fruity science halves fat in chocolate 2
(Date:2/26/2015)... THOUSAND OAKS, Calif. , Feb. 26, 2015 /PRNewswire/ ... has achieved Gold Partner status in Oracle PartnerNetwork. In ... Oracle for its commitment to establish Oracle-related knowledge in ... addressing the challenges of joint customers. Originally ... allows researchers to rapidly zoom in and out of ...
(Date:2/26/2015)... SAN DIEGO , Feb. 26, 2015  Epic ... Prahalad , Ph.D. will present at the 35th Annual ... 2015 at 10:00 a.m. EST in the MIT Room, 3rd Floor. ... Copley Place Hotel in Boston, Mass. Epic is ... real-time detection of genomic and proteomic changes that occur ...
(Date:2/26/2015)...  Spark Therapeutics (NASDAQ: ONCE ) announced ... in the Cowen and Company Health Care Conference on ... the Boston Marriott Copley Place. To access ... the Cowen conference, please visit the "Upcoming Events" section ... Therapeutics website at www.sparktx.com .  A replay of ...
(Date:2/26/2015)... 2015 On Wednesday, February 25, Peggy ... nationwide Clostridium difficile (C. diff) awareness movement, lauded ... by the Centers for Disease Control & Prevention . ... a million infections among Americans in a single year, ... , The study also estimates that 29,000 patients died ...
Breaking Biology Technology:Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... Monday, January 28, The Royal,Marsden Hospital (Sutton, ... Arc Therapy (VMAT)* treatment in the world ... treatment, the hospital,used its existing Elekta Synergy(R) ... system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ), ...
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) ... 2008 Small and Mid Cap Growth Conference in ... at 4:40 p.m. EST. Kevin,Hrusovsky, President and CEO ... the,company,s business. The live webcast can be accessed ...
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
Cached Biology Technology:Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
... CELSR3 CELSR3 is an Orphan-U GPCR ... gene is expressed during development at sites of ... in brain, spinal cord, dorsal root ganglion, and ... blood, brain, colon, heart/melanocyte/uterus, lung, nerve, and placenta ...
Biology Products: